ANTIPHOSPHOLIPID SYNDROME (D ERKAN, SECTION EDITOR)

Current Rheumatology Reports

, 16:405

Management of Recurrent Thrombosis in Antiphospholipid Syndrome

  • Cecilia NalliAffiliated withRheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, Spedali Civili and University of BresciaRheumatology Chair, University of Pavia
  • , Laura AndreoliAffiliated withRheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia
  • , Cinzia CasuAffiliated withRheumatology Unit, Niguarda “Ca’ Granda” Hospital
  • , Angela TincaniAffiliated withRheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

One of the challenges of managing patients with antiphospholipid syndrome is the prevention of rethrombosis (secondary prophylaxis). Risk stratification, i.e. traditional cardiovascular and thrombosis risk factors, systemic autoimmune diseases, antiphospholipid antibody profile, and the intensity of anticoagulation are all relevant to the management of APS patients with recurrent thrombosis. The paper will review “state of the art” strategies for optimizing therapy for APS patients with recurrent thrombosis.

Keywords

Antiphospholipid antibodies Anticardiolipin antibodies Anti-β2glycoprotein I antibodies Lupus anticoagulant Thrombosis Recurrent thrombosis Stroke Primary antiphospholipid syndrome Cardiovascular risk factors Warfarin Low-dose aspirin Hydroxychloroquine Statins Heparin Rituximab Management